ZyVersa Therapeutics Valuation
| ZVSADelisted Stock | 0.15 0.01 7.14% |
ZyVersa Therapeutics seems to be overvalued based on Macroaxis valuation methodology. Our model calculates the value of ZyVersa Therapeutics from examining the company fundamentals such as Shares Owned By Insiders of 0.12 %, current valuation of (2.41 M), and Return On Asset of -0.25 as well as analyzing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that ZyVersa Therapeutics' price fluctuation is out of control at this time. Calculation of the real value of ZyVersa Therapeutics is based on 3 months time horizon. Increasing ZyVersa Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since ZyVersa Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of ZyVersa Stock. However, ZyVersa Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.15 | Real 0.14 | Hype 0.15 |
The real value of ZyVersa Stock, also known as its intrinsic value, is the underlying worth of ZyVersa Therapeutics Company, which is reflected in its stock price. It is based on ZyVersa Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of ZyVersa Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of ZyVersa Therapeutics helps investors to forecast how ZyVersa stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of ZyVersa Therapeutics more accurately as focusing exclusively on ZyVersa Therapeutics' fundamentals will not take into account other important factors: ZyVersa Therapeutics Total Value Analysis
ZyVersa Therapeutics is at this time projected to have valuation of (2.41 M) with market capitalization of 707.14 K, debt of 12.08 M, and cash on hands of . The negative valuation of ZyVersa Therapeutics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the ZyVersa Therapeutics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(2.41 M) | 707.14 K | 12.08 M |
ZyVersa Therapeutics Asset Utilization
One of the ways to look at asset utilization of ZyVersa is to check how much profit was generated for every dollar of assets it reports. ZyVersa Therapeutics maintains a negative usage of resources of -0.25 (%), losing USD0.002479 for each dollar of resources held by the company. Inadequate asset utilization attests that the company is being less effective with each dollar of resources it maintains. Specifically, asset utilization of ZyVersa Therapeutics shows how discouraging it operates for each dollar spent on its resources.ZyVersa Therapeutics Ownership Allocation
Roughly 92.6 (%) of ZyVersa Therapeutics outstanding shares are held by general public with 0.12 % owned by insiders and only 7.28 percent by institutional investors.ZyVersa Therapeutics Profitability Analysis
Net Loss for the year was (9.41 M) with profit before overhead, payroll, taxes, and interest of 0.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates ZyVersa Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in ZyVersa Therapeutics and how it compares across the competition.
About ZyVersa Therapeutics Valuation
The delisted stock valuation mechanism determines ZyVersa Therapeutics' current worth on a weekly basis. Our valuation model uses a comparative analysis of ZyVersa Therapeutics. We calculate exposure to ZyVersa Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of ZyVersa Therapeutics's related companies.ZyVersa Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 1.1 M |
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in ZyVersa Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Other Consideration for investing in ZyVersa Stock
If you are still planning to invest in ZyVersa Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ZyVersa Therapeutics' history and understand the potential risks before investing.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Stocks Directory Find actively traded stocks across global markets | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |